Called Easy Check, the portable check will be sold through Truvian to healthcare professionals for around $15 and has an accuracy rate of more than 98%, according to the company. The check must be made immediately.
“It’s a tape that reminds you a little of a pregnancy matrix,” said Jeff Hawkins, president and CEO of Truvian. “It’s in a single-use package. A drop of blood is charged, a drop of tampon from a dropper bottle that is in the kit and 10 minutes later you get a reading.”
The company, which is developing a compact blood device that aims to deliver effects faster, with less blood and with a lower load than existing systems, has signed agreements with U.S.-based brands. To produce up to 500,000 CoVID-19 day-consistent kits if needed, Hawkins said.
Unlike molecular nasal swab tests that determine whether a user is inflamed with COVID-19, antibody tests are used for whether someone has ever been exposed to the new coronavirus.
This is to perceive immunity and the overall prevalence of the virus in communities, especially since some other people report that they have only mild or non-mild symptoms.
“Truvian’s antibody verification will help us provide key insights that will allow us to better estimate the number of people who in the past felt inflamed from knowing public fitness measures,” said Dr. Jerry Yeo, professor of pathology at the University of Chicago, “and can help increase the availability of remedies like convalescent plasma , which requires blood donations from Americans exposed in the past to COVID-19.”
Antibody tests generally fell out of favor at the beginning of the pandemic due to accuracy issues. The Food and Drug Administration withdrew some past-approved emergency use authorizations and raised thresholds for accuracy testing.
The Truvian check was validated through fitness scientists at UC San Diego, the University of Chicago and the Frederick National Laboratory for Cancer Research. It exceeded the FDA’s existing accuracy needs by detecting the presence of COVID-19 antibodies in 98.44% of positive samples and by failing to locate antibodies in 98.9% of negative samples.
The company’s existing FDA emergency use authorization allows checks to be performed in fitness labs. But Truvian is looking for a authorization at the moment that allows Easy Check to be used outdoors in centralized medical facilities, adding workplaces or emerging verification sites that deliver fast results.